Fundraise / allotmentFiled on BSE ·
Evonile Pharma Board to meet on Oct 8, 2026 to consider rights issue fund-raise
Novartis India · Pharmaceuticals & Biotechnology
What the filing says
- Board meeting scheduled for October 08, 2026 to consider equity shares rights issue
- Equity shares face value ₹5 each; fund-raising subject to approvals and Board terms
- Trading window closed from October 01 to November 05, 2026, covering this Board meeting
Original filing
Board Meeting Intimation for Consideration Of Raising Of Funds Through The Issuance Of Equity Shares Of The Company.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Novartis India
- Acquisition / mergerNovartis India Limited acquires Minipress trademarks from Pfizer for ₹1250 crore
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentBGR Energy Sys.BGR Energy Systems signs Master Restructuring Agreement with NARCL
- Fundraise / allotmentD.P. AbhushanD. P. Abhushan Limited approves preferential issue of equity shares and warrants
- Fundraise / allotmentD.P. AbhushanD. P. Abhushan Limited approves preferential issue of equity shares and warrants
- Fundraise / allotmentD.P. AbhushanD. P. Abhushan Ltd approves preferential issue of equity shares and warrants on Oct 5, 2026
- Fundraise / allotmentOla ElectricOla Electric Mobility Ltd defers Board meeting on Rights Issue scheduled for Oct 5, 2026
- Fundraise / allotmentNexus SelectNexus Select Trust to consider raising up to ₹2,050 Cr in debt on October 12, 2026
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.